$SMMT Summit Therapeutics secures $2 billion investment from AstraZeneca.
By Nexqual Desk ·
Tickers: $SMMT
$SMMT Summit Therapeutics secures $2 billion investment from AstraZeneca.
• AstraZeneca will invest $2.0 billion in convertible preferred shares.
• The deal implies a common stock price of $18.36 per share.
• Companies will also launch a clinical collaboration for ivonescimab.
Source: SEC 8-K, Sep 28, 2026.
1 likes
Posted on Nexqual Sonar — the social network for the stock market. Not financial advice.